Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report

被引：5
|
作者：
Tay, Timothy Kwang Yong [1 ]
Yeong, Joe Poh Sheng [1 ,2 ]
Chen, Eileen Xueqin [3 ]
Sam, Xin Xiu [1 ]
Lim, Johnathan Xiande [1 ]
Chan, Jason Yongsheng [4 ,5 ]
机构：
[1] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore
[2] Inst Mol & Cell Biol, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Mol Pathol, Singapore, Singapore
[4] Duke NUS Med Sch, Oncol Acad Clin Program, Singapore, Singapore
[5] Natl Canc Ctr Singapore, Div Med Oncol, 11 Hosp Crescent, Singapore 169610, Singapore
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
基金：
英国医学研究理事会;
关键词：
MISMATCH REPAIR DEFICIENCY; PD-L1; EXPRESSION; PROTEIN EXPRESSION; SARCOMA;
D O I：
10.1200/PO.22.00068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report
    Takayoshi Fuu
    Kazuyoshi Iijima
    Yukiko Kusama
    Toshiaki Otsuki
    Haruaki Kato
    Journal of Medical Case Reports, 16
  • [32] Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report
    Fuu, Takayoshi
    Iijima, Kazuyoshi
    Kusama, Yukiko
    Otsuki, Toshiaki
    Kato, Haruaki
    JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)
  • [33] Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed-Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis
    Bhatti, Sajjad
    Heldstab, Jaimie
    Lehn, Carolyn
    Tawfik, Ossama
    Ash, Ryan M.
    Hout, David R.
    Seitz, Rob S.
    Bailey, Daniel B.
    O'Dea, Anne P.
    Jensen, Roy A.
    Fan, Fang
    Khan, Qamar J.
    Godwin, Andrew K.
    Sharma, Priyanka
    JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 6
  • [34] Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas
    Driver, Brandon R.
    Miller, Ross A.
    Miller, Tara
    Deavers, Michael
    Gorman, Blythe
    Mody, Dina
    Ge, Yimin
    Barrios, Roberto
    Bernicker, Eric
    Kim, Min
    Cagle, Philip T.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2017, 141 (11) : 1529 - 1532
  • [35] EXPRESSION OF PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) IN MENINGIOMA: CLINICAL UTILITY FOR PREDICTION OF TUMOR RECURRENCE AND ASSOCIATION WITH HYPOXIC RESPONSE AND NFKB2 ACTIVATION
    Karimi, Shirin
    Suppiah, Suganth
    Mansouri, Sheila
    Nassiri, Farshad
    Mamatjan, Yasin
    Liu, Jeff
    Aldape, Kenneth
    Zadeh, Gelareh
    NEURO-ONCOLOGY, 2018, 20 : 150 - 151
  • [36] T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 (vol 37, pg 318, 2019)
    Ott, Patrick A.
    Bang, Yung-Jue
    Piha-Paul, Sarina A.
    Razak, Albiruni R. Abdul
    Bennouna, Jaafar
    Soria, Jean-Charles
    Rugo, Hope S.
    Cohen, Roger B.
    O'Neil, Bert H.
    Mehnert, Janice M.
    Lopez, Juanita
    Doi, Toshihiko
    van Brummelen, Emilie M. J.
    Cristescu, Razvan
    Yang, Ping
    Emancipator, Kenneth
    Stein, Karen
    Ayer, Mark
    Joe, Andrew K.
    Lunceford, Jared K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08) : 688 - 688
  • [37] Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
    Li, Na
    Wan, Zixuan
    Lu, Dongyan
    Chen, Ruilian
    Ye, Xiaowei
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [38] Complete remission after pembrolizumab monotherapy in a non-small cell lung cancer patient with PD-L1 negative, high tumor mutational burden, and positive tumor-infiltrating lymphocytes: A case report
    Li, Suoni
    Ma, Jiequn
    Bai, Jie
    Zhao, Zheng
    MEDICINE, 2024, 103 (49)
  • [39] Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
    Medusa, Paola Maria
    Gilli, Marina
    Notizia, Luca
    Pagliaro, Raffaella
    Carro, Nicola
    Moriello, Alessandro
    D'Agnano, Vito
    Bianco, Andrea
    Perrotta, Fabio
    Vitiello, Fabiana
    MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (04)
  • [40] Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
    Mou, Haibo
    Yu, Lanfang
    Liao, Qin
    Hou, Xuehua
    Wu, Yinfang
    Cui, Qiang
    Yan, Na
    Ma, Ruobing
    Wang, Lingjian
    Yao, Ming
    Wang, Kai
    BMC CANCER, 2018, 18
12345